Onyx Pharma (ONXX) June volatility Flat into Q1 EPS of 27c & ASCO
Tweet Send to a Friend
Onyx Pharma (Nasdaq: ONXX) : ONXX, a developer and marketer of Nexavar, currently approved for the treatment of liver cancer ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


